All In Biotech

Drug Trial Radar · NCT00647530

Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery

FOxTROT - Fluoropyrimidine, Oxaliplatin and Targeted Receptor Pre-Operative Therapy: a Controlled Trial in High-Risk Operable Colon Cancer

Last checked: Nov 19, 2026Latest source record: May 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,053 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,053

Actual

Start

May 15, 2008

Primary completion

Dec 23, 2016

Study completion Dec 31, 2019

Sponsor

Lead sponsor
University of BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 31, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as fluorouracil and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether chemotherapy is more effective with or without panitumumab in treating patients with colon cancer. PURPOSE: This randomized phase III trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high risk operable colon cancer.

Conditions

  • Colorectal Cancer

Interventions

  • panitumumabBiological

  • capecitabineDrug

  • fluorouracilDrug

  • oxaliplatinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Freedom from recurrence or persistent disease (including failure of macroscopic disease clearance at primary surgery) within the first two years following randomizationTime frame: 2 year post randomization
  2. Pathological down-staging as measured by depth of extramural spread among patients allocated to preoperative chemotherapy with or without panitumumabTime frame: Time of surgery

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Birmingham Clinical Trials Unit

    Birmingham, England, United Kingdom

  • Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust

    Birmingham, England, United Kingdom

  • Queen Elizabeth Hospital

    Gateshead, England, United Kingdom

  • Huddersfield Royal Infirmary

    Huddersfield, West Yorks, England, United Kingdom

  • Royal Lancaster Infirmary

    Lancaster, England, United Kingdom

  • Leeds Cancer Centre at St. James's University Hospital

    Leeds, England, United Kingdom

  • Clatterbridge Centre for Oncology

    Metropolitan Borough of Wirral, England, United Kingdom

  • Derriford Hospital

    Plymouth, England, United Kingdom

  • Southport and Formby District General Hospital

    Southport, England, United Kingdom

  • Sandwell General Hospital

    West Bromwich, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.